Are ADCs the new smart bomb or likely to blow up company pipelines without a bye or leave?

We highlighted a number of issues and challenges facing the ADC field in our first ESMO Preview last month.

I really wasn’t expecting to be covering the topic again before the conference next month – how wrong I was in this assumption!

This is an active niche with much going on from one month to the next.

Thie thing is are the next generation versions going to blast through sufficient cancer cells with less toxicities than before or are they going to blow up a few early stage pipelines instead?

After all, it’s easy to forget more early stage agents will fail than succeed.

What kind of features ought we to be looking for and what can we learn from the latest round of company announcements ahead of the ESMO meeting next month?

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by